XClose

Euro Ewing Consortium

International Clinical Trials to Improve Survival from Ewing Sarcoma
Menu

rEECur - Information for patients and carers


The aim of the rEECur trial is to compare four different chemotherapy regimens to find out which is most effective and/or has fewest side effects.

Why is this trial being run?

The trial is comparing four treatments, also known as regimens or arms, called TC, IT, GD and IFOS. These regimens are four commonly used treatments for recurrent Ewing sarcoma. The trial is being run as it is not known which is the best treatment for this group of patients.

Can I take part in the trial?

If you have Ewing sarcoma that has come back after treatment or have primary Ewing sarcoma that is not responding to therapy, you may be able to take part in the trial. Your doctor will explain whether you are able to take part. Your doctor will review your diagnostic tests and medical notes to see if you are eligible to take part in the trial.

What treatment will I receive?

Topotecan and cyclophosphamide (TC)

If you are in this group you will receive at least six cycles of chemotherapy. This means that every three weeks you will have chemotherapy for five days in a row and this will happen six times. Once you have completed the six cycles your doctor may choose to give you some more treatment, either more chemotherapy, radiotherapy or surgery.

If you are in this group you will receive at least six cycles of chemotherapy. This means that every three weeks you will have chemotherapy for five days in a row and this will happen six times. Once you have completed the six cycles your doctor may choose to give you some more treatment, either more chemotherapy, radiotherapy or surgery.

Irinotecan and temozolomide (IT)

If you are in this group you will receive at least six cycles of chemotherapy. This means that every three weeks you will have chemotherapy for five days in a row and this will happen six times. Once you have completed the six cycles your doctor may choose to give you some more treatment, either more chemotherapy, radiotherapy or surgery.

Gemcitabine and docetaxel (GD)

If you are in this group you will receive at least six cycles of chemotherapy. This means that every three weeks you will have chemotherapy on one day in the first week and then on one day in the second week of each treatment cycle and this will happen six times. Once you have completed the six cycles your doctor may choose to give you some more treatment, either more chemotherapy, radiotherapy or surgery.

Ifosfamide (IFOS)

If you are in this group you will receive four cycles of chemotherapy. This means that every three weeks you will have chemotherapy for five days in a row and this will happen four times. Once you have completed the four cycles your doctor may choose to give you some more treatment.


For more detailed information, please go to the following websites:

Country Website
UK
Cancer Research UK
Spain
Registro espanol de estudios clinicos

Can I choose which treatment arm I receive?

No. rEECur is a randomised trial so you will be randomly assigned to a treatment arm by a computer. This is done so that neither you nor your doctor will be able to influence which treatment arm you receive and means that the results of the trial are not biased in any way.

Where is the trial running?

At present (April 2018), the trial is recruiting patients at hospitals in the UK, Spain, Italy, Finland, Norway, Denmark, France, Hungary, Belgium, Poland, Czech Republic, Netherlands and Australia across many sites (pdf).

How many patients will take part?

525 patients will be recruited from across Europe between 2015 and 2019.

How can I find out more information?

  • Read more at Cancer Research UK
  • Print out this information and discuss it with your doctor who will be able to find out more information for you - rEECur patient information (pdf) (this document is currently under review)

How can I take part in the trial?

Talk about the trial with your doctor who will find out if you are eligible and if so, help you to take part.

If you have any questions about this trial, please contact the Cancer Research UK Clinical Trials Unit at the University of Birmingham reecur@trials.bham.ac.uk
***The Trial Office cannot give advice on personal clinical questions***